Could a simple tablet stop epilepsy after a stroke?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: 1. Adults aged 18 to 80 years, of either sex. 2\. Diagnosis of acute ischemic stroke confirmed by clinical presentation and neuroimaging (MRI or CT). 3\. Time from stroke onset to screening/randomization ≤48 hours. 4\. High risk of post-stroke epilepsy, defined as a SeLECT-EEG score ≥7, including: stroke severity (Se, 0-2 points), large-artery atherosclerosis etiology (L, 0-1 point), cortical involvement (C, 0-2 points), middle cerebral artery territory infarction (T, 0-1 point), and EEG findings (EEG, 0-2 points). 5\. No prior history of epilepsy before the index stroke, and no history of other central nervous system disorders (e.g., traumatic brain injury, brain tumor) associated with seizures. 6\. Conscious at enrollment or with recovered consciousness after treatment, and able to cooperate with sublingual medication administration and follow-up assessments. 7\. Provision of written informed consent by the patient or a legally authorized representative. Exclusion criteria: 1. History of epilepsy or occurrence of any seizure prior to screening. 2\. History of ischemic or hemorrhagic stroke within 12 months prior to the index stroke. 3\. Large cerebral infarction with severe intracranial hypertension on imaging after stroke, with limited life expectancy or inability to complete follow-up. 4\. Severe renal impairment (significantly reduced eGFR according to contraindications of edaravone dexborneol) or a history of edaravone-related renal injury. 5\. Severe hepatic dysfunction (ALT or AST \>3 times the upper limit of normal) or severe heart failure (New York Heart Association class III-IV) that may preclude tolerance to the study drug. 6\. Known hypersensitivity to edaravone or borneol, or a history of severe drug allergy. 7\. Pregnant or breastfeeding women; women of childbearing potential unwilling to use effective contraception. 8\. Presence of other serious diseases (e.g., advanced malignancy) that may affect survival or study compliance. 9\. Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation in the study.